Biologic response modifiers and urologic malignancies.
Biologic response modifiers represent a new generation of immunotherapeutic agents. Although biologic response modifiers such as interferon have been moderately successful in treating B-cell malignancies, they have not been as successful for the management of advanced genitourinary malignancies. The measurement of biologic response modifiers in the urine may prove useful for directing intravesical BCG therapy for the treatment of superficial bladder cancer or for directing the use of prophylactic antibiotics for the management of urinary tract infections.
Fleischmann
J
J
Case Western Reserve University School of Medicine, Cleveland, Ohio.
D001500:BCG Vaccine / Q000627:therapeutic use*; D006801:Humans; D007116:Immunization, Passive; D007372:Interferons / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*; D014571:Urologic Neoplasms / Q000628:therapy*
D001500:BCG Vaccine; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D007372:Interferons